SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is facing a sharp sell-off following the cancellation of purchase orders by Celestial AI, now owned by Marvell, which cited a breach of confidentiality obligations regarding shipping disclosures. The community is sharply divided, with bulls pointing to the company's solid underlying technology and cash position as reasons to buy the dip, while critics and short-sellers argue that management's communication failures and delayed disclosure have severely damaged institutional trust and long-term viability.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabet is trending as it deepens its footprint in the AI infrastructure race through reports of a massive potential investment in Anthropic and the development of specialized TPU chips to challenge current hardware monopolies. Investors are closely tracking these developments alongside upcoming earnings, fueling community discussions around Alphabet's ability to maintain its AI dominance and cloud-segment growth.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is facing intense downward pressure and widespread investor frustration as the stock hits fresh lows, with many in the community debating whether the company is headed for bankruptcy, a reverse split, or a potential take-private deal. While some bulls remain focused on the potential of upcoming vehicle launches and backing from major strategic partners, bears continue to point to relentless dilution and significant cash burn as ongoing red flags.

Celestica, Inc. engages in the provision of supply chain solutions globally to equipment manufacturers and service providers. It operates through the Advanced Technology Solutions (ATS) and Connectivity and Cloud Solutions (CCS) segments. The ATS segment includes aerospace and defense, industrial, smart energy, health tech, and capital equipment businesses. The CCS segment consists of enterprise communications, telecommunications, servers, and storage businesses. The company was founded in 1994 and is headquartered in Toronto, Canada.

Celestica, Inc. - Ordinary Shares (Subordinate Voting)

Celestica, Inc.

Celestica is currently the subject of intense community debate as investors weigh strong AI-driven earnings growth and favorable analyst ratings against a recent class-action investigation concerning supply chain news. While many traders view the current volatility as a buying opportunity for a key player in the AI hardware buildout, others remain cautious of price manipulation and the stock's recent struggle to reclaim the $300 level.

Moolec Science SA engages in the development and production of science-based food ingredients. Its products include pet food, animal feed, and dietary supplements. It operates through the following segments: Seed and Integrated Products, Crop Protection, Crop Nutrition, and Emerging Solutions. The company was founded by Gastón Paladini, Henk Hoogenkamp, and Martin Salinas in 2020 and is headquartered in George Town, Cayman Islands.

Moolec Science SA

Moolec Science is currently the focus of heavy social media speculation and high volatility, with traders highlighting its extremely small float and high borrowing costs as catalysts for potential short-squeeze setups. The community remains deeply divided, balancing excitement over proprietary molecular farming breakthroughs against strong warnings regarding the stock's history of reverse splits and significant cash burn.

Rambus, Inc. engages in the provision of cutting-edge semiconductor and Internet Protocol products, spanning memory and interfaces to security, smart sensors and lighting. Its products include Memory Interface Chips, Interface IP, and Security IP. The company was founded by P. Michael Farmwald and Mark A. Horowitz in March 1990 and is headquartered in Sunnyvale, CA.

Rambus Inc.

Rambus is experiencing significant volatility and price swings following a mixed earnings report that missed earnings-per-share expectations despite a revenue beat. The community is actively debating the company's long-term potential as an AI-focused 'pick-and-shovel' play, with some investors viewing the post-earnings pullback as a prime accumulation opportunity while others warn of potential downside due to operational execution risks.

Bed Bath & Beyond, Inc. engages in the provision of an e-commerce platform. It offers furniture and home furnishing products and services. The company was founded on May 5, 1997 and is headquartered in Murray, UT.

Bed Bath & Beyond Inc.

Bed Bath & Beyond Inc

Bed Bath & Beyond is trending as investors debate the viability of the company's "Everything Home" turnaround strategy, with the stock seeing volatile price action fueled by ongoing speculation about potential acquisitions and retail turnaround efforts. The community remains deeply divided, with some traders actively looking for short-squeeze setups and bottom-fishing opportunities, while skeptics express frustration over share dilution and the stock's poor long-term performance.

Domino's Pizza, Inc. engages in the management of a network of company-owned and franchise-owned pizza stores. It operates through the following segments: U.S. Stores, International Franchise, and Supply Chain. The U.S. Stores segment consists primarily of franchise operations. The International Franchise segment comprises a network of franchised stores. The Supply Chain segment manages regional dough manufacturing and food supply chain centers. The company was founded by James Monaghan and Thomas Stephen Monaghan in 1960 and is headquartered in Ann Arbor, MI.

Dominos Pizza Inc

Domino's Pizza is trending as investors react to a recent earnings report that featured a mixed performance, highlighted by an earnings per share miss alongside a slight revenue beat. The community remains focused on the company's ability to drive sales through value-oriented promotions and digital delivery partnerships despite concerns over weak consumer sentiment and rising industry competition.

Erasca, Inc. is a clinical stage precision oncology company. It focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. It has assembled a wholly owned or controlled RAS/MAPK pathway focused pipeline comprising modality-agnostic programs. The company was founded by Jonathan E. Lim and Kevan Shokat on July 2, 2018 and is headquartered in San Diego, CA.

Erasca Inc

Erasca Inc. is facing intense market scrutiny following an 8-K filing that disclosed a patient death in its Phase 1 oncology trial, fueling investor concerns over drug toxicity and trial management. While some retail traders are debating whether the price drop presents a buying opportunity, many community members are aggressively rotating into competitors like Revolution Medicines ($RVMD), citing superior safety profiles and clearer acquisition prospects.

Our vision is to create a global exchange using Ethereum blockchain, where everyone on this planet has the opportunity to buy and sell mobile bandwidth in any country just like you buy foreign currencies on FOREX.

DENT

DENT is currently trending as community members speculate on potential price breakouts, with many sharing long-term price predictions and debating whether the asset is a sleeping giant or a stagnant project. Traders are actively discussing accumulation strategies, analyzing technical patterns, and monitoring volume spikes as they look for signs of a rally.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

PDS Biotechnology (NASDAQ:PDSB) Earns Buy Rating from HC Wainwright

HC Wainwright reaffirmed a "buy" rating and issued a $15.00 target price on shares of PDS Biotechnology in a research note on Wednesday...

Why Is PDS Biotechnology Stock Gaining Wednesday?

PDS Biotechnology says Phase 2 data show higher response rates and survival trends in colorectal cancer and prostate cancer studies.read more...

<ul class="summary-bullets"><li>The trial focused on patients with microsatellite-stable or mismatch repair-proficient metastatic colorectal cancer with liver metastases</li><li>The treatment delivered an ORR of nearly 78%, compared to 35% in a similar trial without the drug.</li><li>Two-year survival exceeded 80%, more than double the 35 - 40% seen in the comparison group.</li></ul>Shares of PDS Biotechnology (PDSB) surged 24% on Wednesday to hit their highest levels since Aug. 27, 2025, after the biotech firm reported promising Phase 2 trial results for its therapy to treat metastatic colorectal cancer.<a href="https://stocktwits.com/symbol/PDSB">PDSB stock</a> recorded its biggest intraday gains since May 26, 2023.<h2 class="st-heading-2">Early Results Show Strong Response Rate</h2>PDS Biotechnology said its investigational immunotherapy, PDS01ADC, demonstrated strong efficacy in a cohort of colorectal cancer patients. In the Phase 2 trial, the treatment delivered an objective response rate (ORR) of nearly 78%, compared to 35% in a similar trial without the drug. Two-year survival exceeded 80%, more than double the 35% to 40% seen in the comparison group.The trial focused on patients with microsatellite stable (MSS) or mismatch repair-proficient (pMMR) metastatic colorectal cancer with liver metastases. The results were published in the Journal of Clinical Oncology (JCO) Oncology Advances on March 10, 2026, the company said.“These early results showing strong tumor response rates and promising patient survival are encouraging and support our approach of subcutaneously administering PDS01ADC to activate the immune system against the cancer,” said Frank Bedu-Addo, President and CEO of PDS Biotech.<h2 class="st-heading-2">How Did Retail Traders React?</h2>One user wondered about a potential buyout, saying the company is “starting to be attractive to the big boys.”<stembedurl>https://stocktwits.com/Mr_Charlie/message/650349765</stembedurl>Another user called the update “great news.”<stembedurl>https://stocktwits.com/rwol9999/message/650343719</stembedurl>Last month, PDS Biotechnology announced updates to its Phase 3 VERSATILE-003 trial, adding progression-free survival as an interim primary endpoint, which could support faster approval of PDS0101 in HPV16-related head and neck cancer.The company also secured new patents in the U.S. and Japan, extending protection into the 2040s.Year-to-date, the stock has gained 47%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

A candlestick chart can be seen in a trading platform on a smartphone. Top U.S. firms announced record buybacks this year. (Photo by Silas Stein/picture alliance via Getty Images)

PDSB Stock Hits 37-Week High — Here’s The Latest On Its Therapy To Treat Metastatic Colorectal Cancer

The biotech firm said its Phase 2 trial of PDS01ADC showed a strong objective response rate and a 24-month survival rate.

Equity

PDS Biotechnology (PDSB) Upgraded to Buy: Here's Why

PDS Biotechnology (PDSB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

<ul class="summary-bullets"><li>The company requested a meeting with the FDA to discuss an accelerated approval pathway for its lead cancer drug, PDS0101, following strong final data from its VERSATILE-002 trial.</li><li>The proposal includes amending the ongoing VERSATILE-003 Phase 3 study to add progression-free survival as an earlier primary endpoint, potentially allowing for an earlier submission.</li><li>Retail traders on Stocktwits flooded discussions with optimism, calling the stock “too cheap” and speculating that the FDA could grant early approval to give patients faster access to the therapy.</li></ul>Shares of PDS Biotechnology logged their best session in more than two months after the late-stage immunotherapy company said it has requested a meeting with the U.S. Food and Drug Administration to discuss an expedited approval pathway for PDS0101, its lead candidate in HPV16-positive head and neck cancer.<h2 class="st-heading-2">FDA Meeting Request</h2>The company said the request follows a review of the final VERSATILE-002 trial data and a proposal to amend the ongoing VERSATILE-003 Phase 3 study. The amendment would reduce the number of patients while maintaining statistical power and add progression-free survival (PFS) as an earlier primary endpoint, alongside median overall survival (mOS).If the PFS endpoint is met, it could allow for an accelerated approval submission to the FDA. While the amendment is under review, the VERSATILE-003 trial will be temporarily paused, though treatment for currently enrolled patients will continue.<h2 class="st-heading-2">Almost 40 Months Of Median Survival</h2>CEO Frank Bedu-Addo said the final survival results from VERSATILE-002 were “very exciting,” noting that it was the first trial in the recurrent or metastatic head and neck cancer population to show a median overall survival of almost 40 months. He added that seeking to include PFS as an earlier primary endpoint could shorten the trial duration.Chief Medical Officer Kirk Shepard said the company’s goal is to pursue the fastest and most cost-effective regulatory path for approval and to provide a non-chemotherapy option for patients who currently lack effective therapies.<h2 class="st-heading-2">Trial Background</h2>VERSATILE-002 is an open-label, multi-center Phase 2 trial evaluating the safety and efficacy of PDS0101, an HPV16-targeted immunotherapy, in combination with pembrolizumab for unresectable, recurrent or metastatic HPV16-positive head and neck cancer.On Stocktwits, retail sentiment for PDS Biotechnology was ‘extremely bullish’ amid a 2,333% surge in 24-hour message volume.<h2 class="st-heading-2">Stocktwits Bulls Bet On Early FDA Nod</h2>One user said the news was “very good” and that the stock looked “way too cheap,” suggesting they were watching for more upside.<stembedurl>https://stocktwits.com/makedatbread88/message/634249334</stembedurl>Another user speculated that the FDA might allow an early approval if PDS agreed to continue trials at the same time, calling it a move that could give very sick head and neck cancer patients access to a potentially life-saving therapy.<stembedurl>https://stocktwits.com/Stockman824/message/634214470</stembedurl><a href="https://stocktwits.com/symbol/PDSB">PDS Biotechnology’s stock</a> has declined 38% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

PDS Biotechnology’s stock (PDSB) has declined 38% so far in 2025. | Image source: Getty Images

PDS Biotechnology Stock Logs Best Session In 2 Months After FDA Fast-Track Push For Cancer Drug — Retail Bets On Early Approval

The company requested a meeting with the FDA to discuss an accelerated approval pathway for its lead cancer drug, PDS0101, following strong final data from its VERSATILE-002 trial.

<ul class="summary-bullets"><li>Q3 revenue of $995.7 million beat Align’s own forecast range of $965 million to $985 million, fueled by strong growth in clear aligners for teens and kids.</li><li>Non-GAAP earnings rose to $2.61 per share, with operating margins improving despite restructuring and impairment charges.</li><li>Retail traders on Stocktwits turned bullish, setting upside targets between $170 and $200 for the stock.</li></ul>Shares of Align Technology rose about 16% in after-hours trading on Wednesday after the Invisalign maker reported third-quarter (Q3) revenue above its own forecast and showed improving momentum in clear aligners for teens and kids.<h2 class="st-heading-2">Results Beat Company Outlook</h2>Align reported Q3 revenue of $995.7 million, up 1.8% year over year and above its guidance range of $965 million to $985 million, though down 1.7% from the prior quarter as the company had flagged. Currency helped, adding about $15.6 million year on year.Clear Aligner revenue was $805.8 million, up 2.4% from a year earlier and flat sequentially. Total clear aligner volume rose 4.9% to 647,800 cases, with the biggest tailwind from younger patients.Treatments for teens and kids jumped 8.3% year over year and 14.7% from Q2 to 256,000 cases, helped by more doctors submitting cases and continued adoption of Invisalign First.The Imaging Systems and CAD/CAM business, which includes iTero scanners, brought in $189.9 million, down 0.6% year over year and 8.6% sequentially, which the company said was normal Q3 capital-equipment seasonality.<h2 class="st-heading-2">Profitability&nbsp;</h2>GAAP operating income was $96.3 million for an operating margin of 9.7%, lower than last year, mainly because the quarter included $88.3 million of restructuring, impairment and accelerated depreciation charges. On a non-GAAP basis, operating margin improved to 23.9%.Net income fell to $56.8 million, or $0.78 per share, from $1.55 a year earlier, largely because of those one-time charges. Non-GAAP EPS was $2.61, up from $2.35.Align ended the quarter with $1 billion in cash and cash equivalents, up from $901 million in the second quarter (Q2).<h2 class="st-heading-2">Outlook</h2>For the fourth quarter (Q4), Align expects revenue of $1.025 billion to $1.045 billion, with clear aligner volume, ASP and systems revenue all seen improving sequentially, and non-GAAP operating margin around 26%.&nbsp;For full-year 2025, the company still expects clear aligner volume to grow in the mid-single digits and revenue to be flat to slightly higher than 2024, reflecting a mixed dental market, especially in North America.<h2 class="st-heading-2">Stocktwits Users Cheer Align’s Strong Quarter</h2>On Stocktwits, retail sentiment for Align was ‘bullish’ amid ‘extremely high’ message volume.One user said Align remains the clear market leader after the quarter and that they were bullish on the stock getting back above $170 by year-end, with a price target of $200 by the first quarter of 2026.&nbsp;<stembedurl>https://stocktwits.com/durocali/message/634224575</stembedurl>Another user said the print was a big beat and flagged $155 as the level to watch on the upside, noting there were still higher gaps to be filled.<stembedurl>https://stocktwits.com/SpudZone/message/634224376</stembedurl><a href="https://stocktwits.com/symbol/ALGN">Align’s stock</a> has declined 37% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, Align Technology logo is displayed on a smartphone with a S&P index website background. (Photo Illustration by Alvin Chan/SOPA Images/LightRocket via Getty Images)

Align Technology Stock Surges After-Hours On Teen Demand — Retail Sees Rally Ahead Into 2026

Q3 revenue of $995.7 million beat Align’s own forecast range of $965 million to $985 million, fueled by strong growth in clear aligners for teens and kids.

Take the Zacks Approach to Beat the Markets: StoneCo, Axon, Intuit in Focus

Shares of PDS Biotechnology Corporation (PDSB) drew investor attention on Thursday after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.pdsbiotech.com/index.php/investors/news-center/press-releases/press-releases1/132-2025-news/980-iotecheportsullear2024inancialesultsandr20250327">reported</a> better-than-feared losses for 2024.PDS Biotechnology reported a loss per share of $1.03 for the year, narrower than the $1.39 reported for 2023 and better than an analyst estimate of $1.11, according to FinChat data.Net loss narrowed to $37.61 million in 2024 compared to $42.94 million in the prior year.The reduced losses, the company said, were primarily due to a decrease in operating expenses.Research and development expenses fell during the year to $22.6 million from $27.8 million a year ago, owing to reduced clinical costs, personnel costs, and professional fees.The company ended the year with a cash balance of $41.7 million.Last month, PDS Biotechnology announced an up to $22 million registered direct offering. The company said the securities purchase agreements with new and existing healthcare-focused institutional investors included $11 million of upfront gross proceeds.It also included up to an additional $11 million of aggregate gross proceeds upon cash exercise in full of warrants issued to the investors.PDS is a late-stage immunotherapy company developing investigational products designed to stimulate and enhance targeted T cell responses against cancers.Earlier this month, the company said that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) application to evaluate a combination of its investigational immunotherapy candidate Versamune MUC1 with a novel investigational tumor-targeting Interleukin 12 to treat colorectal carcinoma in certain patients who failed previous treatment.On Stocktwits, the retail investor sentiment about PDS Biotechnology dropped further into the ‘bearish’ territory (32/100), while message volume remained at the ‘extremely low’ level over the past 24 hours.<figure class="image"><img style="aspect-ratio:647/151;" src="https://news.stocktwits-cdn.com/Screenshot_2025_03_27_at_12_26_56_PM_png_6c503f4d3f.webp" alt="PDSB's Sentiment Meter and Message Volume as of 12:27 p.m. ET on March 27, 2025 | Source: Stocktwits" width="647" height="151"><figcaption>PDSB's Sentiment Meter and Message Volume as of 12:27 p.m. ET on March 27, 2025 | Source: Stocktwits</figcaption></figure>After the company released its earnings report, HC Wainwright analyst Joseph Pantginis lowered the firm’s price target to $13 from $21 while keeping a ‘Buy’ rating on the shares.A Stocktwits user, however, expressed optimism on the company.<stembedurl>https://stocktwits.com/AyR15/message/609402462</stembedurl>Another user opined that the results were “not as bad as predicted.”<stembedurl>https://stocktwits.com/Mr_Charlie/message/609407057</stembedurl><a href="https://stocktwits.com/symbol/PDSB">PDSB shares</a> have lost over 25% this year and over 65% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/cryptocurrency/toncoin-gains-outpace-bitcoin-ethereum-after-musk-grok-ai-goes-beyond-x-to-telegram/chJ2BLTRbEJ">Toncoin Gains Outpace Bitcoin, Ethereum After Musk’s Grok AI Goes Beyond X To Telegram – Retail’s Divided</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

PDS Biotechnology Stock In Spotlight On Better-Than-Feared 2024 Loss – Retail Stays Bearish

The company said the reduced losses were primarily due to decreased operating expenses.  

PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products include PDS0101 and PDS01ADC. The company was founded by Frank K. Bedu-Addo in 2005 and is headquartered in Princeton, NJ.

PDSB
PDS Biotechnology Corporation

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest PDSB News

PDSBPDS Biotechnology Corporation